*ST赛隆：子公司注射用尼可地尔获得药品注册证书

Core Viewpoint - The company has received approval for the injectable Nicorandil from the National Medical Products Administration, which is intended for the treatment of unstable angina pectoris, enhancing its product portfolio [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Hunan Sailong Pharmaceutical (Changsha) Co., Ltd., has recently obtained the drug registration certificate for injectable Nicorandil [1] - The approval of injectable Nicorandil will further enrich the company's formulation varieties [1] Group 2: Market Considerations - The sales performance of the newly approved drug will depend on various internal and external environmental changes, indicating a level of uncertainty [1] - The company commits to timely information disclosure based on subsequent developments [1]